1-20 of 21
Amy J. Johnson
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract 629: Activity of VIP943 on AML patient-derived leukemic blasts and healthy donor-derived bone marrow hematopoietic stem cells

Free
Beatrix Stelte-Ludwig, Tibor Schomber, Melanie M. Frigault, Joseph Birkett, Amy J. Johnson, Anne-Sophie Rebstock, Sebastian Ludwig, Raquel Izumi, Ahmed Hamdy
Journal: Cancer Research
Cancer Res (2024) 84 (6_Supplement): 629.
https://doi.org/10.1158/1538-7445.AM2024-629
Published: 22 March 2024
View articletitled, Abstract 629: Activity of VIP943 on AML patient-derived leukemic blasts and healthy donor-derived bone marrow hematopoietic stem cells
Journal Articles

Abstract 2051: Innovations in ADC technology platform with legumain-cleavable KSP-inhibitor payloads adaptable to various aspects of cancer biology

Free
Hans-Georg Lerchen, Anne-Sophie Rebstock, Mareike Wiedmann, Beatrix Stelte-Ludwig, Amy J. Johnson, Raquel Izumi, Ahmed Hamdy
Journal: Cancer Research
Cancer Res (2024) 84 (6_Supplement): 2051.
https://doi.org/10.1158/1538-7445.AM2024-2051
Published: 22 March 2024
View articletitled, Abstract 2051: Innovations in ADC technology platform with legumain-cleavable KSP-inhibitor payloads adaptable to various aspects of cancer biology
Journal Articles

Abstract 3197: Addressing drug metabolism and pharmacokinetics (DMPK) challenges of small molecule-drug conjugates (SMDCs)

Free
Anne-Sophie Rebstock, Hans-Georg Lerchen, Harvey Wong, Beatrix Stelte-Ludwig, Mareike Wiedmann, Amy J. Johnson, Raquel Izumi, Ahmed Hamdy
Journal: Cancer Research
Cancer Res (2024) 84 (6_Supplement): 3197.
https://doi.org/10.1158/1538-7445.AM2024-3197
Published: 22 March 2024
View articletitled, Abstract 3197: Addressing drug metabolism and pharmacokinetics (DMPK) challenges of small molecule-drug conjugates (SMDCs)
Journal Articles

Abstract 1558: Targeting CDK9 via the small-molecule inhibitor enitociclib as a therapeutic strategy to treat MYCN-amplified rhabdomyosarcoma and neuroblastoma in children

Free
Son Tran, Patrick Sipila, Melanie M. Frigault, Amy J. Johnson, Joseph Birkett, Raquel Izumi, Ahmed Hamdy, Beatrix Stelte-Ludwig, David P. Douglass, Anne-Marie Langevin, Norman J. Lacayo, Aru Narendran
Journal: Cancer Research
Cancer Res (2023) 83 (7_Supplement): 1558.
https://doi.org/10.1158/1538-7445.AM2023-1558
Published: 04 April 2023
View articletitled, Abstract 1558: Targeting CDK9 via the small-molecule inhibitor enitociclib as a therapeutic strategy to treat MYCN-amplified rhabdomyosarcoma and neuroblastoma in children
Journal Articles

Abstract 484: VIP236: A small molecule drug conjugate with an optimized camptothecin payload has significant activity in patient-derived and metastatic cancer models

Free
Beatrix Stelte-Ludwig, Melanie M. Frigault, Hans-Georg Lerchen, Tibor Schomber, Raquel Izumi, Amy J. Johnson, Ahmed Hamdy
Journal: Cancer Research
Cancer Res (2023) 83 (7_Supplement): 484.
https://doi.org/10.1158/1538-7445.AM2023-484
Published: 04 April 2023
View articletitled, Abstract 484: VIP236: A small molecule drug conjugate with an optimized camptothecin payload has significant activity in patient-derived and metastatic cancer models
Journal Articles

Abstract 6294: CXCR5 is a very promising drug target for the development of antibody-drug conjugates to treat patients with lymphoma

Free
Tibor Schomber, Beatrix Stelte-Ludwig, Amy J. Johnson, Oliver von Ahsen, Christoph Schatz, Raquel Izumi, Ahmed Hamdy, Hans-Georg Lerchen
Journal: Cancer Research
Cancer Res (2023) 83 (7_Supplement): 6294.
https://doi.org/10.1158/1538-7445.AM2023-6294
Published: 04 April 2023
View articletitled, Abstract 6294: CXCR5 is a very promising drug target for the development of antibody-drug conjugates to treat patients with lymphoma
Journal Articles

Abstract 1859: VIP152, a selective CDK9 inhibitor, demonstrates sensitivity in gynecologic cell lines that are cisplatin sensitive or resistant and delivers in vivo antitumor efficacy

Free
Melanie M. Frigault, Hermes Garban, Joy M. Greer, Stuart Hwang, Raquel Izumi, Amy J. Johnson, Beatrix Stelte-Ludwig, Ahmed Hamdy
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): 1859.
https://doi.org/10.1158/1538-7445.AM2022-1859
Published: 15 June 2022
View articletitled, Abstract 1859: VIP152, a selective CDK9 inhibitor, demonstrates sensitivity in gynecologic cell lines that are cisplatin sensitive or resistant and delivers in vivo antitumor efficacy
Journal Articles

Abstract 1963: ARQ 531, a potent reversible BTK inhibitor, exhibits potent antitumor activity in ibrutinib-resistant diffuse large B-cell lymphoma

Free
Sudharshan Eathiraj, Yi Yu, Ron Savage, Jennifer A. Woyach, Sean D. Reiff, Amy J. Johnson, Brian Schwartz
Journal: Cancer Research
Cancer Res (2018) 78 (13_Supplement): 1963.
https://doi.org/10.1158/1538-7445.AM2018-1963
Published: 01 July 2018
View articletitled, Abstract 1963: ARQ 531, a potent reversible BTK inhibitor, exhibits potent antitumor activity in ibrutinib-resistant diffuse large B-cell lymphoma
Journal Articles

Abstract 4471: Novel SF3B1 deletion mutations result in aberrant RNA splicing in CLL patients

Free
Anant A. Agrawal, Michael Seiler, Lindsey Brinton, Rose Mantel, Rosa Lapalombella, Jennifer A. Woyach, Amy J. Johnson, Lihua Yu, John C. Byrd, Peter G. Smith, James S. Blachly*, Silvia Buonamici*
Journal: Cancer Research
Cancer Res (2017) 77 (13_Supplement): 4471.
https://doi.org/10.1158/1538-7445.AM2017-4471
Published: 01 July 2017
View articletitled, Abstract 4471: Novel SF3B1 deletion mutations result in aberrant RNA splicing in CLL patients
Journal Articles

Abstract 3014: BCL3 over-expression contributes an in vivo growth advantage in a B-cell lymphoma xenograft model and is a risk factor for ibrutinib relapse in CLL

Free
Timothy L. Chen, Bonnie K. Harrington, Larry Beaver, Amy S. Ruppert, Nyla A. Heerema, Xiaoli Zhang, Hatice Gulcin Ozer, Amy J. Johnson, Jennifer A. Woyach, Erin Hertlein, John C. Byrd
Journal: Cancer Research
Cancer Res (2017) 77 (13_Supplement): 3014.
https://doi.org/10.1158/1538-7445.AM2017-3014
Published: 01 July 2017
View articletitled, Abstract 3014: BCL3 over-expression contributes an in vivo growth advantage in a B-cell lymphoma xenograft model and is a risk factor for ibrutinib relapse in CLL
Journal Articles

Abstract 3150: PLCG2 C2-domain mutations co-occur with BTK and PLCG2 resistance mutations in chronic lymphocytic leukemia undergoing treatment with the BTK inhibitor ibrutinib

Free
Dan Jones, Jennifer A. Woyach, Weiqiang Zhao, Sean Caruthers, Huolin Tu, Joshua Coleman, John C. Byrd, Amy J. Johnson, Gerard Lozanski
Journal: Cancer Research
Cancer Res (2017) 77 (13_Supplement): 3150.
https://doi.org/10.1158/1538-7445.AM2017-3150
Published: 01 July 2017
View articletitled, Abstract 3150: PLCG2 C2-domain mutations co-occur with BTK and PLCG2 resistance mutations in chronic lymphocytic leukemia undergoing treatment with the BTK inhibitor ibrutinib
Journal Articles

Abstract 1207: SNS-062 demonstrates efficacy in chronic lymphocytic leukemia in vitro and inhibits C481S mutated Bruton tyrosine kinase

Free
Catherine A. Fabian, Sean D. Reiff, Daphne Guinn, Linda Neuman, Judith A. Fox, Wendy Wilson, John C. Byrd, Jennifer A. Woyach, Amy J. Johnson
Journal: Cancer Research
Cancer Res (2017) 77 (13_Supplement): 1207.
https://doi.org/10.1158/1538-7445.AM2017-1207
Published: 01 July 2017
View articletitled, Abstract 1207: SNS-062 demonstrates efficacy in chronic lymphocytic leukemia in vitro and inhibits C481S mutated Bruton tyrosine kinase
Journal Articles

Abstract 3985: Characterization of plasma-derived exosomes in CLL reveals a distinct microRNA signature and the BCR regulation in exosome secretion

Free
Yuh-Ying Yeh, Hatice Gulcin Ozer, Amy M. Lehman, Lianbo Yu, Amy J. Johnson, John C. Byrd
Journal: Cancer Research
Cancer Res (2015) 75 (15_Supplement): 3985.
https://doi.org/10.1158/1538-7445.AM2015-3985
Published: 01 August 2015
View articletitled, Abstract 3985: Characterization of plasma-derived exosomes in CLL reveals a distinct microRNA signature and the BCR regulation in exosome secretion
Journal Articles

Abstract 1744: ACP-196: A second generation Btk inhibitor demonstrates biologic activity in a canine model of B-cell non-Hodgkin lymphoma

Free
Heather L. Gardner*, Bonnie K. Harrington*, Raquel Izumi, Ahmed Hamdy, Allard Kaptein, Bart Van Lith, Cheryl A. London, John C. Byrd, Amy J. Johnson, William C. Kisseberth
Journal: Cancer Research
Cancer Res (2014) 74 (19_Supplement): 1744.
https://doi.org/10.1158/1538-7445.AM2014-1744
Published: 01 October 2014
View articletitled, Abstract 1744: ACP-196: A second generation Btk inhibitor demonstrates biologic activity in a canine model of B-cell non-Hodgkin lymphoma
Journal Articles

Abstract 907: Bcl-xL dependence predicts response to alvocidib in chronic lymphocytic leukemia patients

Free
William E. Pierceall, Steven L. Warner, Ryan J. Lena, Camille Doykan, Noel Blake, Michael Elashoff, Daniel D. Von Hoff, David J. Bearss, Michael H. Cardone, Michael Grever, Mark C. Lanasa, John C. Byrd, Amy J. Johnson
Journal: Cancer Research
Cancer Res (2014) 74 (19_Supplement): 907.
https://doi.org/10.1158/1538-7445.AM2014-907
Published: 01 October 2014
View articletitled, Abstract 907: Bcl-xL dependence predicts response to alvocidib in chronic lymphocytic leukemia patients
Journal Articles

Abstract 2557: Immune modulating agent ibrutinib blocks T-helper 17 activation and release of IL-17A while preserving T-regulatory cell function

Free
Carrie S. Yang, Jason A. Dubovsky, Danielle L. Chappell, Bonnie K. Harrington, Samantha Jaglowski, Jennifer A. Woyach, Amy J. Johnson, Natarajan Muthusamy, John C. Byrd
Journal: Cancer Research
Cancer Res (2014) 74 (19_Supplement): 2557.
https://doi.org/10.1158/1538-7445.AM2014-2557
Published: 01 October 2014
View articletitled, Abstract 2557: Immune modulating agent ibrutinib blocks T-helper 17 activation and release of IL-17A while preserving T-regulatory cell function
Journal Articles

Abstract 2578: Synergistic activity of lenalidomide and interleukin-21 in chronic lymphocytic leukemia

Free
Rebekah L. Browning, Jeffrey A. Jones, Amy J. Johnson, Natarajan Muthusamy, John C. Byrd
Journal: Cancer Research
Cancer Res (2014) 74 (19_Supplement): 2578.
https://doi.org/10.1158/1538-7445.AM2014-2578
Published: 01 October 2014
View articletitled, Abstract 2578: Synergistic activity of lenalidomide and interleukin-21 in chronic lymphocytic leukemia
Journal Articles

Abstract 492: Ibrutinib inhibits Interleukin-2 inducible kinase, driving a Th1 selective pressure in human leukemia patients that serves to alleviate tumor-induced immunosupression.

Free
Jason A. Dubovsky, Kyle A. Beckwith, Gayathri Natarajan, Jennifer A. Woyach, Samantha Jaglowski, Joshua Hessler, Ta-Ming Liu, Betty Y. Chang, Karilyn M. Larkin, Matthew R. Stefanovski, Frank W. Frissora, Lisa L. Smith, Kelly A. Smucker, Joseph M. Flynn, Jeffrey A. Jones, Leslie A. Andritsos, Kami Maddocks, Amy M. Lehman, Richard Furman, Jeff Sharman, Anjali Mishra, Michael A. Caligiuri, Abhay R. Satoskar, Joseph J. Buggy, Natarajan Muthusamy, Amy J. Johnson, John C. Byrd
Journal: Cancer Research
Cancer Res (2013) 73 (8_Supplement): 492.
https://doi.org/10.1158/1538-7445.AM2013-492
Published: 15 April 2013
View articletitled, Abstract 492: Ibrutinib inhibits Interleukin-2 inducible kinase, driving a Th1 selective pressure in human leukemia patients that serves to alleviate tumor-induced immunosupression.
Journal Articles

Abstract 5473: The contribution of P-glycoprotein to clinical pharmacokinetic interactions between lenalidomide and temsirolimus

Free
Xiaoxia Yang, Hofmeister C. Craig, Darlene M. Rozewski, Seungsoo Lee, Ping Chen, Amy J. Johnson, Zhongfa Liu, Erinn M. Hade, Jia Ji, Larry J. Schaaf, Don M. Benson, Eric H. Kraut, William J. Hicks, Kenneth K. Chan, Ching-Shih Chen, Sherif S. Farag, Michael R. Grever, John C. Byrd, Mitch A. Phelps
Journal: Cancer Research
Cancer Res (2011) 71 (8_Supplement): 5473.
https://doi.org/10.1158/1538-7445.AM2011-5473
Published: 15 April 2011
View articletitled, Abstract 5473: The contribution of P-glycoprotein to clinical pharmacokinetic interactions between lenalidomide and temsirolimus
Journal Articles

Clinical rebirth of flavopiridol in chronic lymphocytic leukemia (CLL): Utilizing in vitro and in vivo pharmacodynamic measurements to improve efficacy and interrogate relevant mechanism(s) of action

Free
Amy J. Johnson, David M. Lucas, Lisa L. Smith, Jamie M. S. Allison, Thomas S. Lin, Michael R. Grever, John C. Byrd
Journal: Cancer Research
Cancer Res (2005) 65 (9_Supplement): 394.
Published: 01 May 2005
View articletitled, Clinical rebirth of flavopiridol in chronic lymphocytic leukemia (CLL): Utilizing in vitro and in vivo pharmacodynamic measurements to improve efficacy and interrogate relevant mechanism(s) of action